Lodo Therapeutics

About:

Lodo Therapeutics is a drug discovery and development company.

Website: http://lodotherapeutics.com

Top Investors: Eli Lilly, AbbVie, ARCH Venture Partners, WuXi AppTec, Bill & Melinda Gates Foundation

Description:

Lodo Therapeutics Corporation is a drug discovery and development company focused on the creation of naturally derived novel therapeutics that will have a dramatic impact human health on a global basis. Lodo seeks to work in partnership with global pharmaceutical companies and world leading Non-Governmental Organizations (NGO’s) to tackle some of the greatest challenges in human health: resistant infectious disease and cancers. Lodo Therapeutics was created to pursue the scientific vision of Dr. Sean Brady at Rockefeller University. Dr. Brady and his laboratory have developed a genome-based, culture-independent platform for the discovery, biosynthesis, and characterization of small molecules from microbial sources present in soil samples. Lodo believes that the potential cures for a number of deadly and/or debilitating diseases literally lie at our feet. By combining the advancements in DNA sequencing and bioinformatics, this innovative discovery platform exploits the power of microbial evolution for the identification of therapeutically valuable pharmaceutical products derived from natural sources. Lodo Therapeutics, an Accelerator Corporation-backed entity, is headquartered in New York City. The company’s lab and offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science park.

Total Funding Amount:

$17M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

New York, New York, United States

Founded Date:

2016-01-01

Contact Email:

info(AT)lodotherapeutics.com

Founders:

David Pompliano, Sean Brady

Number of Employees:

1-10

Last Funding Date:

2016-01-11

IPO Status:

Private

Industries:

© 2025 bioDAO.ai